McKesson Corporation $MCK Shares Purchased by C WorldWide Group Holding A S

C WorldWide Group Holding A S boosted its position in shares of McKesson Corporation (NYSE:MCK) by 45.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,158 shares of the company’s stock after acquiring an additional 1,622 shares during the quarter. C WorldWide Group Holding A S’s holdings in McKesson were worth $3,985,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of McKesson by 2.0% in the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock valued at $8,846,186,000 after purchasing an additional 232,286 shares during the period. Geode Capital Management LLC lifted its holdings in McKesson by 4.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock worth $2,057,065,000 after buying an additional 112,224 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in McKesson by 150.4% during the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares in the last quarter. Norges Bank purchased a new position in McKesson in the 2nd quarter valued at approximately $1,346,661,000. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of McKesson by 56.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after acquiring an additional 446,060 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.08% of the stock is owned by corporate insiders.

McKesson Stock Performance

MCK opened at $959.34 on Friday. McKesson Corporation has a one year low of $570.51 and a one year high of $971.93. The company has a market cap of $118.41 billion, a P/E ratio of 27.59, a PEG ratio of 1.35 and a beta of 0.40. The business’s 50-day simple moving average is $827.03 and its 200-day simple moving average is $777.93.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 303.62% and a net margin of 1.09%.The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is 9.43%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MCK. TD Cowen increased their price objective on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group lifted their price objective on McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a research report on Wednesday, December 10th. Barclays began coverage on shares of McKesson in a report on Monday, December 8th. They issued an “overweight” rating and a $960.00 target price on the stock. Finally, Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $918.93.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 earnings beat and revenue growth — McKesson reported quarterly EPS above consensus and revenue up ~11.4% year‑over‑year, driven by higher gross profit and operating profit expansion. Business Wire: Q3 Results & Guidance
• Positive Sentiment: Raised FY‑2026 adjusted EPS guidance — Management increased full‑year adjusted EPS to $38.80–$39.20, signaling confidence in specialty drug and oncology/biopharma services growth that underpins margin outlook. Reuters: Boosts 2026 Profit Forecast
• Positive Sentiment: Market reaction — Street enthusiasm around the beat + guidance lift sent shares to multi‑year/all‑time highs and a strong intraday jump as analysts and investors re‑rate growth expectations. Investing.com: Stock Hits All‑Time High
• Neutral Sentiment: Analyst actions mixed — Some firms nudged price targets higher (Wells Fargo, Mizuho) but maintained neutral/equal‑weight stances, so analyst moves are not uniformly bullish. Zacks: Broker View on MCK
• Negative Sentiment: Operational cash‑flow weakness and balance‑sheet items — reporting flagged weaker operating cash flow versus last year and higher total liabilities, which could temper valuation upside if cash conversion doesn’t improve. Insider selling was also noted. QuiverQuant: EPS Beat but Weak Cash Flow

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.